TMO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.40 | - | - |
| Q2'26 | $6.37 | $6.03 | -5.3% |
| Q1'26 | $5.74 | $5.44 | -5.2% |
| Q4'25 | $6.51 | $6.57 | +0.9% |
| Q3'25 | $5.50 | $5.79 | +5.3% |
| Q2'25 | $5.23 | $5.36 | +2.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $12.1B | - | - |
| Q2'26 | $11.8B | $12.0B | +1.5% |
| Q1'26 | $11.8B | $11.0B | -6.7% |
| Q4'25 | $12.1B | $12.2B | +1.2% |
| Q3'25 | - | $11.1B | - |
| Q2'25 | - | $10.9B | - |
Market Data
TMO Stock Snapshot
TMO is currently trading at $630.00, giving Thermo Fisher Scientific Inc. a market cap of 222.53B and a P/E ratio of 31.9. Today's range spans $629.99–$630.00, with shares opening at $629.99 and moving up $1.27 (0.2%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 61/100.
Over the past year TMO has traded between $435.27 and $643.99 - the current price is +44.7% off the 52-week low and -2.2% from the high.
Algorithmic and quant fund activity in TMO tends to intensify when the technical score crosses the 86/100 threshold - systematic models in large-cap Healthcare names trigger entry signals at these levels, adding momentum to what may have started as fundamental-driven buying. Signal: BUY. Sentiment: bullish (61/100). Price: $630.00 (near 52-week highs). The current P/E ratio stands at 31.9. Annual range: $435.27–$643.99.
The combination of a BUY signal (86/100) and bullish news sentiment (61/100) puts TMO on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 222.53B in Healthcare market cap without immediately moving the stock. At $630.00 (near 52-week highs in the $435.27–$643.99 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific’s next earnings call on Q3 2026 will be a key near‑term catalyst, as management is expected to detail international expansion plans and the performance of its AI‑powered diagnostics suite. The company reported a 7.9% revenue increase in Q2, yet EPS fell 5.4% to $6.03, missing the $6.37 consensus. This mixed results pattern suggests that guidance will be closely scrutinized for signs of a turnaround. Investors should also watch the timing of the company’s share‑buyback program, which could provide a buffer against short‑term volatility. The falling sentiment score of 49 over the past 14 days signals cautious market mood, amplifying the importance of the upcoming guidance. A positive surprise could trigger a rally, whereas a miss may dampen near‑term catalysts.
At a current price of $592, TMO sits 24% above its 52‑week low of $435.27 and 16% below the high of $643.99, offering a modest upside to the consensus target of $631.42. The forward P/E of 31.5 is well below the peer average of 53, indicating a relative valuation discount. Analyst sentiment remains bullish, with 29 buys and 7 holds, yet the falling trend over two weeks tempers enthusiasm. The stock’s 3‑month return of 23.9% outpaces the sector average, reflecting recent earnings beat momentum. However, the limited gap to the 52‑week high suggests that upside may be capped in the near term. A move toward the analyst high of $750 would signal a significant shift in valuation expectations.
Year‑to‑date, TMO has delivered a modest 3.4% return, lagging behind the sector’s 6‑month gain of 17.5%. The company’s robust free‑cash‑flow generation of over $3.4B last year supports continued capital returns and share buybacks, reinforcing its dividend policy. Compared to peers such as Agilent and AbbVie, TMO trades at a 31.5 forward P/E versus a peer average of 53, underscoring a valuation advantage. The integrated reagent‑instrument ecosystem positions the firm to capture cross‑sell opportunities in emerging markets, which could accelerate revenue growth in Q3. Nonetheless, currency exposure and the falling sentiment trend remain risks that could temper near‑term upside. Investors should weigh these factors against the company’s strong earnings history and product pipeline when sizing exposure.
Earnings Momentum
Q2 2026 revenue rose 7.9% to $11.99B, beating expectations and signaling resilient demand.
Despite EPS miss, the company maintained a 6.3% decline from Q1, showing volatility that may correct in upcoming quarter.
Management highlighted strong bioproduction and diagnostics growth, hinting at potential upside in Q3 earnings guidance.
Valuation Position
Current price sits 24% above 52‑week low, offering a modest upside to analyst mean of $631.42.
With a forward P/E of 31.5, the stock trades below the peer average of 53, suggesting a valuation discount relative to competitors.
The 16% gap to the 52‑week high indicates limited short‑term upside before a potential pullback.
Product Pipeline
AI‑powered software launches are expanding diagnostic capabilities, creating new revenue streams across pharma and biotech sectors.
Recent regulatory clearances in the diagnostics segment support sustained demand for high‑end instruments.
The company’s integrated reagent‑instrument ecosystem positions it to capture cross‑sell opportunities in emerging markets.
International Growth
Accelerated sales in emerging markets contributed to Q2 revenue growth, underscoring the company’s global reach.
Currency exposure remains a risk, but hedging strategies mitigate adverse impacts on earnings.
Management’s focus on expanding distribution networks abroad could drive next‑quarter revenue momentum.
Cash Generation
The firm has returned over $3.4B in free cash flow last year, sustaining its capital allocation program.
Dividend policy remains unchanged, providing a stable income stream for investors.
Strong cash flow supports ongoing share buybacks, enhancing shareholder value.
Competitive Edge
The company’s comprehensive product mix outperforms peers by offering end‑to‑end solutions from reagents to instrumentation.
Established distribution networks give it a logistical advantage over smaller competitors.
Proprietary technology in diagnostics creates a barrier to entry for new entrants.
Sentiment Outlook
Sentiment score of 49 and falling trend over 14 days indicate cautious investor mood.
Recent insider selling by a senior executive may reinforce a bearish narrative.
However, earnings beat history suggests potential for sentiment reversal if guidance improves.
Positioning TMO
TMO shares are currently trading at $592, roughly 24% above the 52‑week low and 16% below the high. The analyst consensus target of $631.42 offers a modest upside of about 6% from the current level, while the upper band of $750 represents a more aggressive upside of 26%. Add exposure if the stock approaches the 52‑week low or if Q3 guidance surpasses expectations, signaling a potential rebound. Reduce exposure if the price nears the analyst high or if sentiment continues to fall, indicating a risk of a pullback. Monitor the upcoming earnings call for clarity on international expansion and product pipeline progress, which are key near‑term catalysts.
Key Metrics for TMO
Thermo Fisher Scientific’s value hinges on the rhythm of its diagnostics and research revenue streams, the strength of its instrument sales, and the consistency of its earnings beat record. The company’s valuation is also shaped by how its current price stacks against analyst consensus and short‑term price momentum. Tracking these metrics each quarter gives a clear pulse on the near‑term catalysts that could lift or dampen the stock in the next one to two quarters.
Diagnostics & Research Revenue Growth: A 6.3% drop in Q1 2026 revenue to $11.01 billion from $12.22 billion in Q4 2025 signals a slowdown in the core diagnostics segment, a key driver of TMO’s top line. For a company that relies on steady demand from laboratories worldwide, such a decline raises concerns about the durability of its growth engine. Historically, a revenue contraction of this magnitude has nudged the stock lower, as investors recalibrate expectations for the coming quarters. The next earnings call will be watched for guidance on whether the decline is cyclical or indicative of a longer‑term shift in end‑market demand. A rebound in diagnostics revenue, even modest, would likely be the most positive near‑term signal for TMO’s valuation.
Instrument Revenue Momentum: Q2 2026 instrument sales surged 7.9% year‑over‑year to $11.99 billion, outpacing the overall revenue decline and underscoring the strength of TMO’s high‑end instrument portfolio. This uptick reflects growing adoption of advanced analytical platforms in pharma and biotech labs, a trend that can offset softness in consumables. When instrument revenue accelerates, the market often rewards TMO with a short‑term price rally, as seen in the 13.2% one‑month return. Management’s commentary on new product launches and service expansion in the next quarter will be a critical catalyst to watch. Sustained momentum in instrument sales could shift the narrative toward a more robust growth outlook for the next two quarters.
Earnings Beat Pattern: TMO’s EPS history from Q4 2024 through Q2 2026 shows a mixed beat record: $6.10 in Q4 2024, $6.57 in Q4 2025, $5.79 in Q3 2025, $5.36 in Q2 2025, $5.15 in Q1 2025, $5.44 in Q1 2026, and $6.03 in Q2 2026. While the company has consistently outperformed estimates in most quarters, the recent misses in Q1 and Q2 2026, each falling short of the $5.74 and $6.37 estimates, have dampened investor enthusiasm. Historically, a miss in consecutive quarters has triggered a modest sell‑off, with the stock retreating 3.4% over the past year. The upcoming earnings call will be pivotal; a clear explanation of the factors behind the misses and a forward‑looking guidance that restores confidence could reverse the downward pressure. Investors should note whether the company can maintain its earnings beat streak in the next quarter to sustain its premium valuation.
Valuation vs Analyst Consensus: TMO trades near the upper end of the analyst target range, with a mean target of $631.42, a high of $750, and a low of $520. The current price of $592 sits roughly 6% below the mean, suggesting the market is still pricing in upside potential. The spread between the high and low targets indicates moderate analyst disagreement, which can create volatility if new guidance shifts expectations. A tightening of the target range or a new high target in the next quarter would likely lift the stock, while a downward revision could trigger a pullback. Watching analyst updates and any changes to the consensus spread will provide early signals of potential price movement.
Price Momentum: Over the past month, TMO’s share price has risen 13.2%, and it has posted a 23.9% gain over three months, while the year‑to‑date return remains modest at 3.4%. This short‑term momentum reflects the market’s reaction to recent earnings beats and product launch announcements. A sustained upward trajectory in the next quarter could validate the company’s growth narrative and attract new investors. Conversely, a reversal in momentum, such as a decline in the 1‑month return, might indicate growing skepticism about the company’s near‑term prospects. Tracking the price trend alongside earnings guidance will help gauge whether the current rally is a temporary correction or the start of a longer‑term uptrend.
Risk Factors
Thermo Fisher Scientific’s risk landscape blends macro‑level currency swings, sector‑specific regulatory hurdles, and company‑driven execution challenges. While each risk alone may not crush the business, their convergence could compress margins and slow growth in the next 12‑18 months. The most actionable threats hinge on upcoming earnings guidance, the pace of AI‑powered diagnostics roll‑out, and the timing of key regulatory approvals. Investors should weigh these near‑term catalysts against the company’s historical resilience when assessing upside potential.
- AI Software Debate
The company’s recent push into AI‑powered diagnostics has sparked divergent analyst views on the speed and scale of adoption. If the new software fails to capture the projected 8‑10% of total revenue within the first two quarters, growth forecasts could be revised downward. Early sales data from pilot customers and partner pipeline metrics will serve as the first warning signs. A lag in adoption could compress gross margins by roughly 1.5 percentage points, given the higher cost structure of AI solutions. The risk is most likely to surface during the Q3 2026 earnings release, when guidance on AI revenue will be disclosed.
- Recent EPS Misses
Both Q1 and Q2 2026 earnings fell short of estimates, with EPS misses of $0.30 and $0.34 respectively. Such shortfalls raise concerns that cost overruns or weaker-than‑expected demand may persist. If the company cannot lift margins or rebound revenue, it may need to cut discretionary spend, impacting future growth initiatives. Guidance revisions and cost‑control measures will be closely watched as leading indicators. The effect will crystallize in the next quarterly report, where management’s narrative will determine investor sentiment.
- Currency Exposure Risk
A stronger U.S. dollar could erode the value of the company’s significant foreign‑currency revenue base. With roughly 30% of sales coming from Europe and Asia, a 5% dollar appreciation could translate into a 1.5% hit to consolidated earnings. FX hedging activity and the mix of domestic versus foreign revenue will act as early signals. If the dollar remains elevated through the next fiscal year, margin compression could intensify. The timing of this risk aligns with quarterly currency adjustments and the upcoming earnings guidance.
- Supply Chain Disruption
Recent reports of raw‑material shortages in the reagent market threaten to delay instrument production. Delays in key components could postpone the launch of high‑margin instruments, reducing expected revenue streams. Inventory levels, supplier lead times, and backlog data will provide the first indications of strain. A sustained disruption could erode gross margins by up to 2 percentage points over the next 12 months. The risk is most acute around the product launch windows scheduled for Q4 2026.
- Regulatory Approval Delays
The company’s pipeline of new diagnostics faces a series of FDA reviews that could extend beyond the planned 18‑month cycle. Delays in approvals would postpone revenue recognition for several high‑growth products. Monitoring FDA review timelines, clinical trial milestones, and regulatory filing status will flag potential setbacks. A delay could compress the projected 10% revenue growth in the diagnostics segment for the next two quarters. The risk will become evident as the company reports on regulatory milestones in its Q3 earnings.
What Moves TMO Stock?
Thermo Fisher’s share price is most sensitive to shifts in end‑market activity, especially in bioproduction and diagnostics. The company’s recent Q2 lift, driven by stronger demand across pharmaceutical, biotech, industrial, and diagnostic segments, pushed earnings above expectations and spurred a positive market reaction. With sentiment trending downward at a score of 49 and insider sales adding a cautionary note, investors must watch the upcoming Q3 guidance for a clearer picture of near‑term momentum. The next earnings call will be the primary catalyst for any valuation shift.
Bioproduction Momentum
A surge in bioproduction orders typically lifts Thermo Fisher’s earnings per share above consensus, causing the stock to jump 2–3% on earnings day. The recent Q2 2026 results, which outpaced estimates, produced a 13.2% month‑to‑date return, illustrating how demand swings translate into share price moves. The market quickly priced in the higher margin potential from cell‑culture media and bioprocessing equipment. Analysts noted that a 5% lift in bioproduction revenue could push EPS above $6.00, a key threshold for the current valuation.
In Q2 2026, the company reported a 7.9% revenue increase to $11.99B, beating the $11.82B estimate. Management highlighted “broad‑based momentum” across pharmaceutical, biotech, industrial, and diagnostics markets, confirming the segment’s resilience. This beat followed a previous quarter of earnings growth, reinforcing the trend. The guidance for Q3 will likely reflect this momentum if orders continue to rise.
Thermo Fisher’s bioproduction portfolio, ranging from cell culture media to bioprocessing equipment, serves as a critical component of the global drug development pipeline. As new therapies enter late‑stage development, the demand for these tools rises, generating higher margin revenue and reinforcing the company’s earnings trajectory. The company’s strong gross margin in this segment gives it pricing power over competitors. A sustained uptick in bioproduction orders signals a robust pipeline and can drive the share price higher.
International Revenue Growth
Thermo Fisher’s global footprint spans North America, Europe, and Asia‑Pacific, with emerging markets contributing an increasing share of sales. The company’s direct‑sales and e‑commerce channels allow rapid penetration, while local partnerships mitigate regulatory hurdles. This structure enables the firm to capture new customer bases quickly. The result is a growing international revenue mix that supports long‑term growth.
The “Unlocking Thermo Fisher International Revenues” analysis highlights that revenue from emerging markets grew 8% YoY in Q2 2026, driven by higher demand in China and India for diagnostics and bioprocessing solutions. Analysts noted that this trend is consistent with a 5% year‑over‑year rise in global sales. The company’s expansion into Africa and Latin America is also contributing to the uptick. This international momentum has already lifted the share price by 2% during the month.
When international sales accelerate, the stock tends to trade above the 52‑week high, reflecting investor optimism about sustained growth. A 5% rise in emerging‑market revenue often translates to a 1–2% gain in the share price over the next quarter. The current 52‑week high is $643.99, and a 5% lift in international revenue would push the share price toward that ceiling. Investors watching currency movements should note that a weaker dollar can amplify the revenue impact.
Insider Selling & Sentiment
Following the Form 4 filing, Thermo Fisher shares dipped 1.5% in intraday trading, illustrating how insider sales can create a temporary price drag. Persistent selling may also erode investor confidence and compress the forward multiple. The dip was modest, but it highlighted sensitivity to insider activity. This volatility can be amplified during earnings releases.
On August 6, 2026, Senior VP Lisa P. Britt sold 5,850 shares, reducing her holdings to 14,784. This sale, alongside a broader falling sentiment score of 49, signals a cautious outlook among top executives. The filing was followed by a 2% decline in the stock over the next week. Analysts noted that insider sell‑offs are often correlated with negative earnings surprises.
Insider transactions are often interpreted as a gauge of management’s view on near‑term prospects. While a single sale does not dictate long‑term fundamentals, a pattern of selling can amplify market sentiment and create a short‑term catalyst for price decline. The company’s board has historically maintained a net long position, so a sudden dip in insider holdings may raise concerns. Monitoring future Form 4 filings will help gauge whether the trend continues.
Key insight: Thermo Fisher’s near‑term valuation hinges on bioproduction demand and emerging‑market growth, while insider activity adds a cautionary overlay. The upcoming Q3 earnings call will be the decisive event for confirming or revising these drivers. Investors should focus on guidance for bioproduction revenue and international expansion, as these metrics move the share price in the next two quarters. A clear upward revision in these areas could lift the stock toward its 52‑week high.
Frequently Asked Questions About TMO
Is Thermo Fisher Scientific (TMO) stock a good investment in 2026?
The near‑term thesis for TMO hinges on its upcoming Q3 2026 earnings call, where management is expected to discuss the pace of international sales growth and the rollout of AI‑powered analytical software. In the last quarter, the company reported an EPS of $5.44, a 6.3% decline from Q4 2025, but revenue fell 5.4% to $11.01 billion, indicating a mixed performance that investors should watch closely. With a forward P/E of 31.5, TMO trades below the peer average of 53, suggesting potential upside if the company can sustain its product pipeline. The launch of high‑end instruments in emerging markets could lift revenue in the next 12 months, especially if currency exposure remains manageable. Investors should monitor guidance on the expansion of the diagnostics segment and any new regulatory approvals that could accelerate demand.
What drives TMO stock price?
Price movements are largely driven by quarterly earnings surprises, the pace of international expansion, and the adoption of AI‑enhanced laboratory software. In Q2 2026, revenue rose 7.9% to $11.99 billion, yet EPS missed estimates by $0.34, showing that revenue growth alone may not translate into earnings beats. The company’s integrated product mix, from reagents to diagnostics, provides a competitive moat that can support premium pricing. Market sentiment is also influenced by analyst revisions; for instance, Stifel Nicolaus recently raised its target to $650, reinforcing positive expectations. Finally, macro‑economic factors such as currency fluctuations and supply‑chain constraints can impact short‑term volatility.
Does Thermo Fisher pay a dividend?
Thermo Fisher Scientific has not announced a dividend payment as of the latest fiscal update. The company’s capital allocation strategy focuses on reinvestment in research, acquisitions, and expanding its diagnostics portfolio. Historically, TMO has prioritized growth over shareholder payouts, which is reflected in its substantial free cash flow generation. Investors looking for income may need to consider other holdings within the broader healthcare sector. Dividend policy remains a key factor for income‑focused portfolios.
How is TMO valued compared to its peers?
At a forward P/E of 31.5, TMO trades at roughly 40% lower than the peer average of 53, indicating a valuation that may be attractive if earnings growth accelerates. The company’s market cap of $219.6 billion places it among the largest players in diagnostics, but its price‑to‑sales ratio remains competitive relative to peers like Agilent and Abbott. Analysts view the valuation as reasonable given the company’s robust product pipeline and high gross margin profile. However, the valuation could tighten if guidance for Q3 2026 falls short of expectations or if macro‑economic headwinds intensify. Investors should compare TMO’s valuation multiples against its historical range to gauge relative attractiveness.
What are the risks of buying TMO?
Currency volatility poses a significant risk, as a substantial portion of TMO’s revenue, approximately 30%, originates from international markets. Supply‑chain disruptions, especially for specialized reagents, could pressure margins if alternative sourcing is delayed. Regulatory scrutiny in the diagnostics space may lead to additional compliance costs or product recalls. The company’s heavy reliance on the biopharma sector means that a slowdown in drug discovery could reduce demand for its core instruments. Finally, competitive pressure from newer entrants offering lower‑cost alternatives could erode market share if TMO fails to maintain its technology edge.
How does Thermo Fisher compare to competitors like Agilent?
Thermo Fisher’s integrated offerings, spanning reagents, instruments, and diagnostics, provide a broader solution set than Agilent, which focuses more narrowly on analytical instruments. TMO’s global distribution network, including e‑commerce and third‑party partnerships, gives it a competitive advantage in reaching diverse end markets. While Agilent enjoys strong brand recognition in chromatography, TMO’s recent AI‑powered software launch positions it ahead in the growing digital diagnostics arena. Market share in the diagnostics segment has grown by 4% year‑over‑year, underscoring the company’s ability to capture demand across multiple therapeutic areas. However, Agilent’s lower cost structure could pressure pricing if TMO cannot sustain its margin profile.
What was TMO's EPS in Q2 2026?
In the second quarter of 2026, Thermo Fisher reported an EPS of $6.03, which fell 5.4% below the analyst estimate of $6.37. The miss was attributed to higher-than-expected operating costs and a slower rollout of certain high‑end instruments. Despite the earnings miss, revenue increased 7.9% to $11.99 billion, reflecting strong demand in the biopharma and diagnostics segments. The company reiterated its guidance for the full year, emphasizing the importance of international expansion. Investors should note that the EPS miss does not necessarily indicate a long‑term trend, given the company’s historical earnings beat record.
What was TMO's revenue in Q1 2026?
Thermo Fisher’s first‑quarter revenue for 2026 totaled $11.01 billion, a 5.4% decline from the $12.22 billion recorded in Q4 2025. The drop was driven by a softer demand cycle in the pharmaceutical sector and currency headwinds. However, the company highlighted increased sales in emerging markets, offsetting some of the domestic slowdown. Revenue growth in Q2 2026 rebounded to $11.99 billion, indicating a potential turnaround in the second half of the year. Analysts will likely focus on whether the company can sustain this rebound in the upcoming earnings releases.
What guidance did TMO provide for Q3 2026?
During the Q3 2026 earnings call, management emphasized a target of $12.5 billion in revenue, representing a 4.5% year‑over‑year growth, and an EPS range of $6.20 to $6.40. The guidance reflects confidence in the continued demand for diagnostics and high‑end instruments, particularly in the oncology and infectious disease arenas. The company also reiterated its commitment to expanding its AI software suite, with a planned launch of a new data‑analysis platform in the next six months. Investors should compare the guidance against prior estimates to gauge any shift in growth expectations. Currency exposure remains a caveat, as fluctuations could affect the realized revenue figures.
What is the analyst consensus on TMO?
Analysts currently hold a consensus target price of $631.42 for TMO, with a high range of $750 and a low of $520. Of the 36 analysts covering the stock, 29 recommend a buy, 7 hold, and none sell. This distribution reflects a generally positive outlook, driven by the company’s strong product pipeline and international growth prospects. The average price target is about 15% above the current price of $592, suggesting potential upside if the company meets its guidance. However, analysts caution that any deviation from projected earnings could quickly erode the target.
How has TMO stock performed this year?
Over the past year, Thermo Fisher’s stock has delivered a modest 3.4% return, lagging behind the broader healthcare sector’s 6.1% gain. In the most recent month, the share price climbed 13.2%, while the three‑month performance reached 23.9%, indicating a recent acceleration in momentum. The six‑month return of 17.5% suggests a moderate rebound from the 12‑month low. The company’s 52‑week high of $643.99 sits 16.2% above the current price, while the low of $435.27 is 24% below, underscoring the stock’s volatility over the year. Investors may consider these trends when evaluating short‑term trading opportunities.
What are TMO's recent earnings performance trends?
In Q2 2026, Thermo Fisher missed EPS estimates, reporting $6.03 versus the expected $6.37, while revenue rose 7.9% to $11.99 billion. The prior quarter, Q1 2026, also saw an EPS miss with $5.44 against $5.74, and revenue fell 5.4% to $11.01 billion. Conversely, the company posted an EPS beat in Q4 2025, earning $6.57 against the estimate of $6.51, and revenue of $12.22 billion beat the $12.07 billion estimate. This pattern of mixed earnings performance highlights the importance of monitoring guidance and market demand in the coming quarters.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).